Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen

Antiviral Therapy

Volumn 17, Issue 1, 2012, Pages 119-123

  Marcelin, Anne Genevieve ^a   Descamps, Diane ^b   Tamalet, Catherine ^c   Cottalorda, Jacqueline ^d   Izopet, Jacques ^e   Delaugerre, Constance ^f   Morand Joubert, Laurence ^g   Trabaud, Mary Anne ^h   Bettinger, Dominique ⁱ   Rogez, Sylvie ^j   Ruffault, Annick ^k   Henquell, Cecile ^l   Signori Schmuck, Anne ^m   Bouvier Alias, Magali ⁿ   Vallet, Sophie ^o   Masquelier, Bernard ^p   Flandre, Philippe ^a   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h CROIX ROUSSE HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o BREST UNIVERSITY HOSPITAL   (France)

^p BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MOLECULAR TYPING; MUTATION; NEVIRAPINE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84856144713     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1886     Document Type: Article

References (13)

1. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448. (Pubitemid 32959067)
2. Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to firstand second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009; 11:165-173.
3. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686. (Pubitemid 39577672)
4. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782. (Pubitemid 41433197)
5. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503-514.
6. Tambuyzer L, Vingerhoets J, Azijn H, et al. Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies. AIDS Res Hum Retroviruses 2010; 26:1197-1205.
7. Marcelin AG, Flandre P, Descamps D, et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother 2010; 54:72-77.
8. Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78:153-160. (Pubitemid 43132558)
9. Tambuyzer L, Azijn H, Rimsky LT, et al. Compilation and prevalence of mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2009; 14:103-109.
10. The French ANRS (National Agency for AIDS Research) AC11 Resistance group. ANRS algorithm version. (Updated 1 May 2011. Accessed 1 July 2011.) Available from www.hivfrenchresistance.org.
11. Haddad M, Stawiski E, Benhamida J, Coakley E. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 574.
12. Asahchop EL, Tremblay CL, Brenner BG, et al. In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes. International HIV and Hepatitis Virus Drug Resistance Workshop. 8-12 June 2010, Dubrovnik, Croatia. Abstract 108.
13. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.